Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers

被引:3
|
作者
Keske, Aysenur [1 ]
Weisman, Paul [1 ]
Ospina-Romero, Monica [1 ]
Raut, Prachi [1 ]
Smith-Simmer, Kelcy [2 ,3 ]
Zakas, Anna L. [2 ,3 ]
Flynn, Christopher [1 ]
Xu, Jin [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA
[2] Univ Wisconsin, Master Genet Counselor Studies, Acad Affairs, Sch Med & Publ Hlth, Madison, WI USA
[3] Univ Wisconsin, Oncol Genet, UW Hlth, Carbone Canc Ctr, Madison, WI USA
关键词
Hereditary breast cancer; MUTYH; Breast cancer with divergent grade/biomarker status; COLORECTAL-CANCER; RISK;
D O I
10.1007/s10549-023-07173-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Breast cancer patients referred to genetic counseling often undergo genetic testing with broad panels that include both breast cancer susceptibility genes as well as genes more specific for extramammary sites. As a result, patients are often incidentally found to have germline mutations in genes that are not necessarily related to breast cancer risk. One such gene is MUTYH. To understand the role MUTYH may play in breast cancer, the clinicopathological features of patients with monoallelic MUTYH germline mutation and breast cancer were examined.Methods The clinicopathological characteristics of the breast cancers from patients with monoallelic MUTYH mutation were compared to breast cancer patients with other germline mutations in known breast cancer susceptibility genes, including ATM, BRCA1/2, CHEK2, and PALB2. The breast cancer patients who received genetic counseling but tested negative for the aforementioned gene mutations were used as a control group.Results Histologic characteristics of the breast cancers arising in monoallelic MUTYH mutation carriers had significantly larger tumor size, higher tumor grade, and more high-risk biomarker profiles (i.e., Her2-positive and triple-negative) than breast cancer patients with susceptibility genes, except for BRCA1. MUTYH mutation carriers also showed a trend of more frequent intratumoral divergency in terms of tumor grade and biomarker profiles.Conclusion Although germline monoallelic MUTYH mutation is not thought to confer a meaningfully increased risk of breast cancer development, it may contribute to pathological aggressiveness and diversity of breast cancers when they sporadically arise in MUTYH carriers.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 50 条
  • [21] Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
    Kengo Ikejima
    Sayuri Tokioka
    Kazuyo Yagishita
    Yuka Kajiura
    Naoki Kanomata
    Hideko Yamauchi
    Yasuyuki Kurihara
    Hiroko Tsunoda
    Journal of Medical Ultrasonics, 2023, 50 : 213 - 220
  • [22] Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
    Morganti, Stefania
    Jin, Qingchun
    Vincuilla, Julie
    Buehler, Ryan
    Ryan, Sean
    Stokes, Samantha
    Parker, Tonia
    Mittendorf, Elizabeth A.
    King, Tari A.
    Weiss, Anna
    Partridge, Ann H.
    Bychkovsky, Brittany L.
    Curigliano, Giuseppe
    Tayob, Nabihah
    Lin, Nancy U.
    Garber, Judy E.
    Tolaney, Sara M.
    Lynce, Filipa
    NPJ BREAST CANCER, 2024, 10 (01)
  • [23] Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
    Ikejima, Kengo
    Tokioka, Sayuri
    Yagishita, Kazuyo
    Kajiura, Yuka
    Kanomata, Naoki
    Yamauchi, Hideko
    Kurihara, Yasuyuki
    Tsunoda, Hiroko
    JOURNAL OF MEDICAL ULTRASONICS, 2023, 50 (02) : 213 - 220
  • [24] Factors influencing gynecologic risk reduction surgeries for BRCA1 or BRCA2 germline mutation carriers
    Hagemann, Andrea
    Blachut, Barbara
    Bhat, Amrita
    Mullen, Mary
    Thaker, Premal
    McCourt, Carolyn
    Mutch, David
    Powell, Matthew
    Khabele, Dineo
    Kuroki, Lindsay
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S147 - S147
  • [25] Pathologic Features and Immunophenotype of Estrogen Receptor-positive Breast Cancers in BRCA1 Mutation Carriers
    Kaplan, Jennifer S.
    Schnitt, Stuart J.
    Collins, Laura C.
    Wang, Yihong
    Garber, Judy E.
    Montgomery, Kelli
    West, Robert B.
    Krag, Karen
    Fetten, Katharina
    Lincoln, Anne
    Tung, Nadine M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (10) : 1483 - 1488
  • [26] Germline BRCA mutation in male carriers—ripe for precision oncology?
    Ricardo Romão Nazário Leão
    Aryeh Joshua Price
    Robert James Hamilton
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 48 - 56
  • [27] Overview on population screening for carriers with germline BRCA mutation in China
    Lei, Huijun
    Zhang, Min
    Zhang, Luyao
    Hemminki, Kari
    Wang, Xiao-jia
    Chen, Tianhui
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Immunophenotype of ductal carcinoma in situ in BRCA germline mutation carriers
    van der Groep, Petra
    van Diest, Paul
    van der Wall, Elsken
    CELLULAR ONCOLOGY, 2008, 30 (02) : 180 - 181
  • [29] Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status
    Stjepanovic, Neda
    Wilson, Michelle K.
    Oza, Amit M.
    Clarke, Blaise
    Berman, Hal K.
    Amir, Eitan
    Mackay, Helen
    Shaw, Patricia
    Butler, Marcus O.
    Mulligan, Anna Marie
    Milea, Anca
    Ahmed, Lailah
    Volenik, Alexandra
    Wang, Lisa
    Pugh, Trevor John
    Stockley, Tracy
    Kim, Raymond H.
    Siu, Lillian L.
    Kamel-Reid, Suzanne
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Q and A: A New Standard of Care for Germline BRCA1 and/or BRCA2 Mutation Carriers With Early-Stage Breast Cancer
    Desai, Neelam V.
    Zakalik, Dana
    Somerfield, Mark R.
    Tung, Nadine M.
    JCO ONCOLOGY PRACTICE, 2022, 18 (06) : 427 - +